The last WHO classification (5th Edition, 2021) integrated a TERT promoter mutation or a homozygous deletion of CDKN2A and/or CDKN2B as new criteria for the recognition of grade 3 meningiomas. This evidence concerns the gene CDKN2A and meningioma.